NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

94-AR-0066

Sponsoring Institute

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: N/A
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

None

Special Instructions

Currently Not Provided

Keywords

Systemic Lupus Erythematosus;
Natural History

Recruitment Keyword(s)

Lupus Nephritis;
Lupus;
Systemic Lupus;
SLE

Condition(s)

Systemic Lupus Erythematosus

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Institute of Arthritis and Musculoskeletal and Skin Diseases

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

Patients 10 years of age and older with known or suspected SLE and their relatives may be eligible for this study. Patients will be evaluated with a medical history and physical examination, blood and urine tests. Other procedures may include:

1. Electrocardiogram

2. 24-hour urine collection

3. Imaging studies, such as chest and joint X-rays, magnetic resonance imaging (MRI) scans, bone scans, and bone densitometry.

4. Questionnaire about the degree of disease activity, and survey of risk factors for disease complications.

5. Apheresis Collection of plasma (fluid portion of blood) or blood cells for analysis. Whole blood is collected through a needle in an arm vein. The blood circulates through a machine that separates it into its components. The required component (plasma or cells) is removed and the rest of the blood is returned to the body through the same needle or through a second needle in the other arm.

6. Skin biopsy Removal of a small skin sample for microscopic analysis. An area of skin is numbed with an anesthetic and a small circular portion (about 1/4 inch in diameter) is removed, using a sharp cookie cutter-type instrument.

7. Kidney, bone marrow or other organ biopsy Removal of a small sample of organ tissue. These biopsies are done only if they can provide information useful in better understanding the disease or making treatment decisions.

8. Genetic studies Collection of a blood sample for gene testing.

Patients will be followed at least once a year with a brief history and physical examination and routine blood and urine tests. Some patients may be seen more often. Treatment recommendations will be offered to patients' physicians, and patients who are eligible for other research treatment studies will be invited to enroll.

Participating relatives of patients will fill out a brief medical history questionnaire and provide a DNA sample (either a blood sample or tissue swab from the inside of the cheek) for genetic testing.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-SLE or suspected SLE established by ACR criteria

-Ability to give informed consent

-Adult and minor relatives (first and second degree) of individuals Included in IV-G (only for genetic studies)

-Ability of the patient or minor relative s parents to give informed consent

EXCLUSION CRITERIA:

-Concomitant medical problems which would confound the interpretation of studies gathered by this protocol. Included in this is the presence of HIV in the blood, active malignancies, or other significant medical conditions that may interferes with interpretation of some lupus studies.

-Concomitant medical, surgical or other conditions for which inadequate facilities are available to support their care at NIH.

-Inability or unwillingness to comply with follow up requirements (e.g. distance, social, physical limitations)

-Any comorbidity of medical or psychological/psychiatric condition or treatment after reviewing of patients previous or outside medical records, that in the opinion of the Principal Investigator, would exclude the subjects from the research studies (e.g. Patient

requiring urgent and/or acute medical care, surgical or other procedures)

-Unwilling to participate in research studies or to provide research samples or data

CRITERIA FOR HEALTHY CONTROL SUBJECTS:

-Inclusion Criteria:

--Age 18 years with no upper age limit.

--For vascular studies healthy control subjects will be age- and gender-matched.

--For genetic studies only: Minor relatives (first and second degree) of SLE subjects Included in section IV-G.

--Ability to give informed consent or minor relative s parents to give informed consent (for genetic studies only).

-Exclusion Criteria:

--Any concomitant medical problems or are taking medications which would confound the interpretation of studies they are considered for

EXCLUSION CRITERIA FOR VASCULAR STUDIES ONLY, FOR SLE AND HEALTHY CONTROLS:

-Subjects with a contraindication to MRI scanning will not receive the optional PET/MRI. These contraindications include subjects with the following devices:

--Central nervous system aneurysm clips

--Implanted neural stimulator

--Implanted cardiac pacemaker or defibrillator

--Cochlear implant

--Ocular foreign body (e.g. metal shavings)

--Implanted Insulin pump

--Metal shrapnel or bullet

-Subjects with a BMI >40 will also not receive the PET MRI.

-Subjects with renal excretory dysfunction, estimated glomerular filtration rate < 60 mL/min/1.73m(2) body surface area according to the Modification of Diet in Renal Disease criteria, will not receive the cardiac CT angiography, or gadolinium contrast agent during the PET/MRI.

-Pregnant or lactating women will be excluded from vascular studies.

-Healthy controls with known history of coronary artery disease, peripheral vascular disease or atherosclerosis.

-Individuals younger than 18 years old will be excluded given the radiation exposure as well as the lack of proper validation for the proposed vascular function studies.


--Back to Top--

Citations:

Systemic lupus erythematosus: ermerging concepts Part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, mobidity and mortality, and pathogenesis

Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus

Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Sarfaraz A. Hasni, M.D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
BG 10-CRC RM 3-2340
10 CENTER DR
BETHESDA MD 20814
(301) 451-1599
hasnisa@mail.nih.gov

Yenealem Temesgen-Oyelakin, R.N.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institutes of Health
Building 10
Room 6N216
10 Center Drive
Bethesda, Maryland 20892
(301) 451-4990
yenealem.temesgen-oyelakin@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010
PRPL@cc.nih.gov

Clinical Trials Number:

NCT00001372

--Back to Top--